Scott & White Memorial Hospital

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Scott & White Healthcare

University of Colorado

Scott & White Healthcare (Swh)

Scott, Sherwood and Brindley Foundation

Frankel, Arthur E.

Arthur E Frankel

Stephen H Leppla

Brad St Croix

Yunpeng Su

David M Neville

Jung-Hee Woo

Thomas Flaig

Andrew Thorburn

Michael L Glode

The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells. In other embodiments, the methods of the present invention relate to ex vivo purging of bone marrow or peripheral blood to remove cells that express one or more subunits of the interleukin-3 receptor such that the purged bone marrow or peripheral blood is suitable, e.g., for autologous stem cell transplantation to restore hematopoietic function.

Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Methods for inhibiting hematopoietic tumor cells with diphtheria tokin-interleukin-3 conjugates

The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.

Antibodies to tumor endothelial marker 8

Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.

Fold-back diabody diphtheria toxin immunotoxin and methods of use

The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the fusion protein is administered intravesically into the cancerous bladder.

Compositions and methods for treating bladder cancer

Methods for treating acute myeloid leukemia with diphtheria toxin-interleukin-3 conjugates

Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate

Growing community of inventors

Temple, TX, United States of America

Arthur E Frankel